Immatics Appoints Venkat Ramanan as Chief Financial Officer
Immatics (NASDAQ: IMTX), a clinical-stage biopharmaceutical company focused on PRAME targeting, has appointed Venkat Ramanan, Ph.D., as Chief Financial Officer, effective immediately. Dr. Ramanan brings over 25 years of experience from prominent companies including Seagen, Gilead Sciences, and Amgen.
The new CFO joins from Anthos Therapeutics, where he previously served as CFO, and succeeds Arnd Christ. Dr. Ramanan's appointment comes at a crucial time as Immatics prepares for the commercial launch of anzu-cel, their PRAME cell therapy for metastatic melanoma patients. His extensive experience includes facilitating product launches, establishing global operations, and enabling corporate transactions.
Immatics (NASDAQ: IMTX), una società biofarmaceutica in fase clinica focalizzata sul targeting PRAME, ha nominato Venkat Ramanan, Ph.D., come Chief Financial Officer, con effetto immediato. Il dottor Ramanan porta oltre 25 anni di esperienza maturata in aziende di rilievo tra cui Seagen, Gilead Sciences e Amgen.
Il nuovo CFO proviene da Anthos Therapeutics, dove ha ricoperto in precedenza il ruolo di CFO, e succede ad Arnd Christ. La nomina di Ramanan avviene in un momento cruciale mentre Immatics si prepara al lancio commerciale di anzu-cel, la loro terapia cellulare PRAME per pazienti con melanoma metastatico. La sua vasta esperienza comprende facilitare i lanci di prodotto, stabilire operazioni globali e abilitare operazioni societarie.
Immatics (NASDAQ: IMTX), una compañía biofarmacéutica en fase clínica centrada en el targeting de PRAME, ha designado a Venkat Ramanan, Ph.D., como Director Financiero, con efecto inmediato. El Dr. Ramanan aporta más de 25 años de experiencia procedentes de empresas destacadas como Seagen, Gilead Sciences y Amgen.
El nuevo CFO procede de Anthos Therapeutics, donde se desempeñó previamente como CFO, y reemplaza a Arnd Christ. El nombramiento de Ramanan llega en un momento clave mientras Immatics se dispone a lanzar comercialmente anzu-cel, su terapia celular PRAME para pacientes con melanoma metastásico. Su amplia experiencia incluye facilitar lanzamientos de productos, establecer operaciones globales y habilitar transacciones corporativas.
임마틱스(Immatics, NASDAQ: IMTX)는 PRAME 타깃에 중점을 둔 임상단계 생물의약기업으로, Venkat Ramanan 박사를 최고재무책임자(CFO)로 즉시 임명했다. Ramanan 박사는 Seagen, Gilead Sciences, Amgen을 포함한 주요 기업에서 25년이 넘는 경력을 보유하고 있다.
새로운 CFO는 이전에 CFO로 재직했던 Anthos Therapeutics에서 합류했으며 Arnd Christ를 대신한다. Ramanan의 임명은 메타스 melanoma 환자를 위한 PRAME 세포치료제 anzu-cel의 상업적 출시를 준비 중인 Immatics에게 중요한 시점에 이루어졌다. 그의 풍부한 경력에는 제품 출시를 촉진하고, 글로벌 운영을 구축하며, 기업 거래를 가능하게 하는 일이 포함된다.
Immatics (NASDAQ: IMTX), société biopharmaceutique en phase clinique axée sur la cible PRAME, a nommé Venkat Ramanan, Ph.D., en qualité de Directeur Financier, avec effet immédiat. Le Dr Ramanan apporte plus de 25 années d'expérience acquises chez des entreprises de premier plan telles que Seagen, Gilead Sciences et Amgen.
Le nouveau CFO vient d'Anthos Therapeutics, où il était auparavant CFO, et succède à Arnd Christ. La nomination de Dr. Ramanan intervient à un moment crucial alors qu'Immatics prépare le lancement commercial d'anzu-cel, leur thérapie cellulaire PRAME pour les patients atteints de mélanome métastatique. Son expérience inclut notamment le pilotage de lancements de produits, la mise en place d'opérations mondiales et la conduite de transactions d'entreprise.
Immatics (NASDAQ: IMTX), ein in der klinischen Phase befindliches Biopharmaunternehmen, das sich auf PRAME-Targeting konzentriert, hat Venkat Ramanan, Ph.D., zum Chief Financial Officer ernannt, mit sofortiger Wirkung. Dr. Ramanan bringt über 25 Jahre Erfahrung aus renommierten Unternehmen wie Seagen, Gilead Sciences und Amgen mit.
Der neue CFO kommt von Anthos Therapeutics, wo er zuvor als CFO tätig war, und tritt die Nachfolge von Arnd Christ an. Die Bestellung von Dr. Ramanan erfolgt zu einem entscheidenden Zeitpunkt, da Immatics sich auf den kommerziellen Markteintritt von anzucel, ihrer PRAME‑Zelltherapie für Patienten mit metastasiertem Melanom, vorbereitet. Zu seinen umfangreichen Erfahrungen gehören die Unterstützung von Produkteinführungen, der Aufbau globaler Operationen und die Ermöglichung von Unternehmense Transaktionen.
إيماتيكس (ناسداك: IMTX)، شركة أدوية حيوية في المرحلة السريرية تركز على استهداف PRAME، عيّنت فينكات رامانان، دكتوراه، كمدير مالي، وذلك اعتباراً من اليوم. يجلب الدكتور رامانان أكثر من 25 عاماً من الخبرة من شركات بارزة مثل Seagen وGilead Sciences وAmgen.
ينضم المستشار المالي الجديد من Anthos Therapeutics، حيث شغل سابقاً منصب CFO، خلفاً لأرد كريست. تأتي تعيين الدكتور رامانان في وقت حاسم بينما تستعد إيماتيكس لإطلاق تجاري لـ anzu-cel، علاجها الخلوي PRAME لمرضى الميلانوما المتقدمة. تتضمن خبرته الواسعة تسهيل إطلاق المنتجات، وتأسيس عمليات عالمية، وتمكين المعاملات المؤسسية.
Immatics（纳斯达克股票代码：IMTX），一家专注于 PRAME 靶向的临床阶段生物制药公司，已任命 Venkat Ramanan，博士，担任首席财务官，任命即时生效。Ramanan 博士在包括 Seagen、Gilead Sciences 和 Amgen 在内的知名公司拥有超过25 年的经验。
新任 CFO 来自 Anthos Therapeutics，此前担任 CFO，接替 Arnd Christ。Ramanan 博士的任命在 Immatics 准备将 PRAME 细胞治疗药物 anzucel 商业化上市之际至关重要，该药用于转移性黑色素瘤患者。其丰富的经验包括促成产品上市、建立全球运营并推动企业交易。
- None.
- Departure of current CFO during crucial pre-commercialization phase
- Potential transition period may impact operational continuity
Houston, Texas and Tuebingen, Germany, October 1, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today announced the appointment of Venkat Ramanan, Ph.D., as Chief Financial Officer (“CFO”), effective immediately. Dr. Ramanan is a seasoned financial leader in the biopharmaceutical industry with over 25 years of experience at companies including Seagen, Gilead Sciences and Amgen. He brings deep financial expertise in facilitating successful product launches, establishing scalable operations in global markets and enabling corporate transactions. He joins Immatics from Anthos Therapeutics, a Novartis company, where he served as CFO. He will succeed Immatics’ current CFO, Arnd Christ.
“We are thrilled to welcome Venkat to Immatics as an accomplished and passionate biopharmaceutical leader. His extensive experience will be instrumental in enabling us to continue to advance our PRAME franchise as well as rapidly move our PRAME cell therapy, anzu-cel, toward commercialization and to patients with a significant unmet medical need,” said Harpreet Singh, Ph.D., Chief Executive Officer and Co-Founder of Immatics. “I would also like to extend our gratitude to Arnd Christ for his financial leadership and tremendous contributions that have brought Immatics to where it stands today. On behalf of the entire team, I wish him all the best in his future endeavors.”
“This is a pivotal moment to join Immatics as the company advances toward its first commercial launch and works to bring its innovative PRAME cell therapy, anzu-cel, to patients with metastatic melanoma,” said Venkat Ramanan, Ph.D., Chief Financial Officer of Immatics. “I look forward to collaborating closely with the team during this dynamic stage of growth and supporting the transition to a commercial-stage organization. Together, we will further strengthen Immatics’ position as the global leader in precision targeting of PRAME, united by our commitment to making a meaningful impact on the lives of patients with cancer.”
Dr. Ramanan brings more than 25 years of experience and leadership in finance, strategy and operations across large and small biopharmaceutical companies, with a proven track record of leading companies through periods of successful transformation and growth. He joins Immatics from Anthos Therapeutics, a clinical-stage biotechnology company acquired by Novartis in April 2025, where he served as CFO. Previously, he was CFO at Turnstone Biologics, where he led the company’s transition from a private to public company through its IPO. Earlier, as Senior Vice President Finance at Seagen, he oversaw the finance department enabling multiple product launches, global expansion and strategic transactions. He also held senior finance and business leadership roles at Gilead Sciences and Amgen. He began his career in the biopharmaceutical industry as a consultant with ZS Associates. Dr. Ramanan holds a Ph.D. in Engineering Mechanics from The Ohio State University.
About Immatics
Immatics is committed to making a meaningful impact on the lives of patients with cancer. We are the global leader in precision targeting of PRAME, a target expressed in more than 50 cancers. Our cutting-edge science and robust clinical pipeline form the broadest PRAME franchise with the most PRAME indications and modalities, spanning TCR T-cell therapies and TCR bispecifics.
Immatics intends to use its website www.immatics.com as a means of disclosing material non-public information. For regular updates, you can also follow us on LinkedIn and Instagram.
Forward-Looking Statements
Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or the Company’s future financial or operating performance. For example, statements concerning timing of data read-outs for product candidates, the timing, outcome and design of clinical trials, the nature of clinical trials (including whether such clinical trials will be registration-enabling), the timing of IND, CTA or BLA filings, estimated market opportunities of product candidates, the Company’s focus on partnerships to advance its strategy, and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “plan”, “target”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in the Company’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission (SEC). Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. The Company undertakes no duty to update these forward-looking statements. All the scientific and clinical data presented within this press release are – by definition prior to completion of the clinical trial and a clinical study report – preliminary in nature and subject to further quality checks including customary source data verification.
For more information, please contact:
Media
Trophic Communications
Phone: +49 151 74416179
Email: Immatics@trophic.eu
Immatics N.V.
Jordan Silverstein
Head of Strategy
Phone: +1 346 319-3325
Email: InvestorRelations@immatics.com
- END -
Attachment
FAQ
Who is the new CFO of Immatics (NASDAQ: IMTX)?
What is Venkat Ramanan's previous experience before joining Immatics?
Why did Immatics (IMTX) appoint a new CFO in October 2025?
Who did Venkat Ramanan replace as CFO at Immatics?
What are Immatics' main products and focus areas?
